{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T12:42:16Z","timestamp":1692276136096},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T00:00:00Z","timestamp":1185926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Treat Options Gastro"],"published-print":{"date-parts":[[2007,8]]},"DOI":"10.1007\/s11938-007-0073-4","type":"journal-article","created":{"date-parts":[[2008,3,15]],"date-time":"2008-03-15T10:46:26Z","timestamp":1205577986000},"page":"305-311","source":"Crossref","is-referenced-by-count":6,"title":["Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions\u2014A debate: Con"],"prefix":"10.1007","volume":"10","author":[{"given":"Luc\u00eda C.","family":"Fry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"M\u00f6nkem\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,3,16]]},"reference":[{"key":"73_CR1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N. Vakil","year":"2006","unstructured":"Vakil N, van Zenten SV, Kahrilas P, et al.: The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101:1900\u20131920.","journal-title":"Am J Gastroenterol"},{"key":"73_CR2","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/S0016-5085(97)70025-8","volume":"112","author":"G.R. Locke","year":"1997","unstructured":"Locke GR, Talley J, Fett SL, et al.: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112:1448\u20131456.","journal-title":"Gastroenterology"},{"key":"73_CR3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/0140-6736(90)90287-F","volume":"335","author":"A.G. Klauser","year":"1990","unstructured":"Klauser AG, Schindlbeck NE, Muller-Lissner SA: Symptoms in gastro-oesophageal reflux disease. Lancet 1990, 335:205\u2013208.","journal-title":"Lancet"},{"key":"73_CR4","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1572-0241.2006.00829.x","volume":"101","author":"J. Labenz","year":"2006","unstructured":"Labenz J, Nocon M, Lind T, et al.: Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease. Am J Gastroenterol 2006, 101:2457\u20132462.","journal-title":"Am J Gastroenterol"},{"key":"73_CR5","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/00365520510011579","volume":"40","author":"J. Ronkainen","year":"2005","unstructured":"Ronkainen J, Aro P, Storskrubb T, et al.: High prevalence of gastroesophageal reflux symptoms and esophagitis with or without symptoms in the general adult Swedish population: a Kalixanda study report. Scand J Gastroenterol 2005, 40:275\u2013285.","journal-title":"Scand J Gastroenterol"},{"key":"73_CR6","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.3748\/wjg.v11.i28.4291","volume":"11","author":"J. Labenz","year":"2005","unstructured":"Labenz J, Malfertheiner P: Treatment of uncomplicated reflux disease. World J Gastroenterol 2005, 11:4291\u20134299.","journal-title":"World J Gastroenterol"},{"key":"73_CR7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2036.2003.01423.x","volume":"17","author":"S.D. Martinez","year":"2003","unstructured":"Martinez SD, Malagon IB, Garewal HS, et al.: Non-erosive reflux disease (NERD)\u2014acid reflux and symptom patterns. Aliment Pharmacol Ther 2003, 17:537\u2013545.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR8","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/gut.2004.042143","volume":"54","author":"P. Malfertheiner","year":"2005","unstructured":"Malfertheiner P, Lind T, Willich S, et al.: Prognostic influence of Barrett\u2019s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut 2005, 54:746\u2013751.","journal-title":"Gut"},{"key":"73_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11938-007-0056-5","volume":"10","author":"A. Trivedi","year":"2007","unstructured":"Trivedi A, Long JD: Heartburn refractory to proton-pump inhibitors. Curr Treat Options Gastroenterol 2007, 10:47\u201356.","journal-title":"Curr Treat Options Gastroenterol"},{"key":"73_CR10","doi-asserted-by":"crossref","first-page":"965","DOI":"10.3109\/00365529709011211","volume":"32","author":"T.L. Venables","year":"1997","unstructured":"Venables TL, Newland RD, Patel AC, et al.: Omeprazole 10 milligrams once daily, omeprazole 20 mg once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms in general practice. Scand J Gastroenterol 1997, 32:965\u2013973.","journal-title":"Scand J Gastroenterol"},{"key":"73_CR11","doi-asserted-by":"crossref","first-page":"974","DOI":"10.3109\/00365529709011212","volume":"32","author":"T. Lind","year":"1997","unstructured":"Lind T, Havelund T, Carlsson R, et al.: Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997, 32:974\u2013979.","journal-title":"Scand J Gastroenterol"},{"key":"73_CR12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2036.2003.01771.x","volume":"18","author":"P.O. Katz","year":"2003","unstructured":"Katz PO, Castell DO, Levine D: Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 2003, 18:875\u2013883.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR13","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2036.2004.02085.x","volume":"20","author":"D. Armstrong","year":"2004","unstructured":"Armstrong D, Talley NJ, Lauritsen K, et al.: The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004, 20:413\u2013421.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR14","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0016-5085(03)00545-6","volume":"124","author":"P.J. Kahrilas","year":"2003","unstructured":"Kahrilas PJ: Refractory heartburn. Gastroenterology 2003, 124:1941\u20131945.","journal-title":"Gastroenterology"},{"key":"73_CR15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00042737-199802000-00004","volume":"10","author":"R. Carlsson","year":"1998","unstructured":"Carlsson R, Dent J, Watts R, et al.: Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998, 10:119\u2013124.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"73_CR16","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1365-2036.1999.00564.x","volume":"13","author":"T. Lind","year":"1999","unstructured":"Lind T, Havelund T, Lundell L, et al.: On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis\u2014a placebo-controlled randomized trial. Aliment Pharmacol Ther 1999, 13:907\u2013914.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.2001.00943.x","volume":"15","author":"N.J. Talley","year":"2001","unstructured":"Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al.: Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of \u2018on-demand\u2019 therapy for 6 months. Aliment Pharmacol Ther 2001, 15:347\u2013354.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR18","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00042737-200208000-00008","volume":"14","author":"N.J. Talley","year":"2002","unstructured":"Talley NJ, Venables TL, Green JR, et al.: Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. Eur J Gastroenterol Hepatol 2002, 14:857\u2013863.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"73_CR19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2036.2004.02155.x","volume":"20","author":"H.H. Tsai","year":"2004","unstructured":"Tsai HH, Chapman R, Shepherd A, et al.: Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004, 20:657\u2013665.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl4","key":"73_CR20","first-page":"A106","volume":"53","author":"E. Bayerd\u00f6rffer","year":"2004","unstructured":"Bayerd\u00f6rffer E, Sipponen P, Bigard M, et al.: Esomeprazole 20 mg continuous versus on demand treatment of patients with endoscopy-negative reflux disease (ENRD) [abstract]. Gut 2004, 53(Suppl 4):A106.","journal-title":"Gut"},{"key":"73_CR21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","volume":"97","author":"D.O. Castell","year":"2002","unstructured":"Castell DO, Kahrilas PJ, Richter JE, et al.: Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002, 97:575\u2013583.","journal-title":"Am J Gastroenterol"},{"key":"73_CR22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2036.2005.02339.x","volume":"21","author":"M.B. Fennerty","year":"2005","unstructured":"Fennerty MB, Johanson JF, Hwang C, Sostek M: Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2005, 21:455\u2013463.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2005.02368.x","volume":"21","author":"J. Labenz","year":"2005","unstructured":"Labenz J, Armstrong D, Lauritsen K, et al.: A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005, 21:739\u2013746.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10620-005-9062-4","volume":"51","author":"C. Schmitt","year":"2006","unstructured":"Schmitt C, Lightdale CJ, Hwang C, Hamelin B: A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006, 51:844\u2013850.","journal-title":"Dig Dis Sci"},{"key":"73_CR25","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10620-005-9071-3","volume":"51","author":"C.J. Lightdale","year":"2006","unstructured":"Lightdale CJ, Schmitt C, Hwang C, Hamelin B: A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci 2006, 51:852\u2013857.","journal-title":"Dig Dis Sci"},{"key":"73_CR26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2036.2005.02553.x","volume":"22","author":"S. Sjostedt","year":"2005","unstructured":"Sjostedt S, Befrits R, Sylvan A, et al.: Daily treatment with esomeprazole is superior to that taken on-demand for maintenance of healed erosive oesophagitis. Aliment Pharmacol Ther 2005, 22:183\u2013191.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1572-0241.2001.03443.x","volume":"96","author":"D.A. Johnson","year":"2001","unstructured":"Johnson DA, Benjamin SB, Vakil NB, et al.: Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001, 96:27\u201334.","journal-title":"Am J Gastroenterol"},{"key":"73_CR28","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1046\/j.1365-2036.2001.01024.x","volume":"15","author":"N.B. Vakil","year":"2001","unstructured":"Vakil NB, Shaker R, Johnson DA, et al.: The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001, 15:927\u2013935.","journal-title":"Aliment Pharmacol Ther"},{"key":"73_CR29","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cgh.2006.03.006","volume":"4","author":"K.R. Devault","year":"2006","unstructured":"Devault KR, Johanson JF, Johnson DA, et al.: Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol 2006, 4:852\u2013859.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"73_CR30","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MEG.0b013e32801055d5","volume":"19","author":"K.L. Goh","year":"2007","unstructured":"Goh KL, Benamouzig R, Sander P, et al.: Efficacy of pantoprazole 20 mg daily compared with esomeprazole 20 mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial \u2014 the EMANCIPATE study. Eur J Gastroenterol Hepatol 2007, 19:205\u2013211.","journal-title":"Eur J Gastroenterol Hepatol"}],"container-title":["Current Treatment Options in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-007-0073-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11938-007-0073-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11938-007-0073-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:56:37Z","timestamp":1559422597000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11938-007-0073-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,8]]}},"alternative-id":["73"],"URL":"https:\/\/doi.org\/10.1007\/s11938-007-0073-4","relation":{},"ISSN":["1092-8472","1534-309X"],"issn-type":[{"value":"1092-8472","type":"print"},{"value":"1534-309X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8]]}}}